Drugs Made In America Acquisition II (DMII)
Blank-check company seeking a pharmaceutical-focused business combination.
$10.17
At close+0.02 (+0.15%)
In millions of USD, except per-share figures
| In millions | Q3 FY24Sep 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Operating income | 0 | 0 | 0 | 0 | −1 | 0 | 0 |
| 0 | 0 | 0 | 0 | 5 | 4 | 5 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 4 | 5 |
| Income before tax | 0 | 0 | 0 | 0 | 4 | 4 | 4 |
| Net income from continuing operations | 0 | 0 | 0 | 0 | 4 | 4 | 4 |
| Net income | 0 | 0 | 0 | 0 | 4 | 4 | 4 |
| EPS, basic | $0.00 | −$0.00 | $0.00 | −$0.02 | $0.18 | $0.07 | $0.07 |
| EPS, diluted | $0.00 | −$0.00 | $0.00 | −$0.02 | $0.17 | $0.07 | $0.07 |
| Weighted average shares, basic | 64 | 64 | 33 | 3 | 13 | 50 | 50 |
| Weighted average shares, diluted | 64 | 64 | 33 | 3 | 13 | 50 | 50 |
| EBITDA | 0 | 0 | 0 | 0 | −1 | 0 | 0 |
| EBIT | 0 | 0 | 0 | 0 | −1 | 0 | 0 |